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Abstract
Introduction
The subjective assessment of the adequacy of informed consent for clinical trials, and the
potential difficulties associated with it, has led several studies to develop objective measures
of informed consent for clinical trials. These objective measures of informed consent are
often specific to a particular population or clinical condition and largely focus on understand-
ing of (some or all of) the key elements of informed consent. Many of the developed tools
are study-specific, but some validated measures exist. Of these validated measures, those
which are reported by participants are of particular interest. Whether these objective tools
conceptualize and measure informed consent in the same way is not known. As such, it is
not clear whether meta-analyzing data from studies reporting different tools is worthwhile.
The aim of this systematic review was to critically appraise the evidence on the overall con-
ceptualisation and item content of validated patient reported measures of informed consent
for clinical trials, and to identify core domains of potential importance for informed consent.
Methods
A systematic search of the literature was conducted to identify relevant articles that
described the development, and/or validation, of patient-reported measures of adequacy of
informed consent for randomised controlled trials. Data was synthesised by classifying the
items identified into domains and sub-domains which were determined by the nomenclature
reported in included studies. Both for descriptions of included studies and of the instruments
reported in those studies, descriptive statistics were used to describe general information
and instrument detail. A narrative synthesis of the instruments and their inter-related
domains and subdomains was conducted to identify areas of both convergence and
divergence.
Results
The search identified 8193 citations. After screening titles and abstracts, 29 full text articles
were retrieved for further assessment. Of these 29, 14 complied with our pre-specified inclu-
sion criteria with 15 not being eligible. Of the 14 instruments, three explicitly reported a theo-
retical or conceptual framework underpinning their development, a further three implicitly
referred to the ‘conceptual dimensions of informed consent’ or ‘principles of research ethics’
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One hundred and seventy nine items were included across the 14 instruments. The primary
focus of the instruments was on understanding. Five core domains were identified which
included: Autonomy; Consequences; Expectations; Purpose; and Individualisation. There
was substantial variability in the coverage of different domains across measures.
Conclusions
This study demonstrated the variability in the theoretical underpinning, development and
domain coverage of existing patient-reported measures of informed consent for clinical tri-
als. The conceptualisation of informed consent could benefit from being extended from a
narrow focus on understanding to include broader considerations of decision-making.
Meaningful involvement of potential trial participants during development of measures criti-
cal for tool relevance is also lacking. The identification of the key domains relevant to all
stakeholders which could be measured to assess the informed consent process for clinical
trials is needed.
Introduction
Before patients can be recruited in to a clinical trial there is both a legal and ethical require-
ment that they have given their informed consent to be involved [1]. This ethical and juridical
requirement, enshrined in the Declaration of Helsinki and other international regulations, was
established as a mechanism to protect potential participants from any undue harm from
research [1, 2]. In broad terms, informed consent for research covers aspects such as capacity,
disclosure, understanding, voluntariness and permission [3]. Due to the randomised nature of
clinical trials and the subsequent loss of treatment choice conferred within the design, the
stakes for participants are often deemed higher than other research studies and as such the reg-
ulatory requirements become further prescriptive. The requirements are such that the
informed consent ‘process’ for clinical trials usually includes both verbal and written informa-
tion that explains (as a minimum) the purpose and aim of the trial, research procedures, antici-
pated risks and benefits, end of trial provisions, source of funding, potential conflicts of
interest, and researchers institutional affiliation [1]. In addition, potential trial participants
should be aware of their right to refuse participation and the ability to withdraw consent at any
time. For consent to be considered valid, in accordance with existing regulatory frameworks, it
must be voluntary, informed and with the individual providing consent having sufficient
capacity to do so [1,2]. The Declaration of Helsinki states that ‘After ensuring that the potential
subject has understood the information’ the researcher should seek the participant’s freely
given informed consent [1]. In addition to the current guidance, the Clinical Trials Regulation
(which will come into effect within the European Union in 2019) states that for consent to be
valid ‘it shall be verified that the subject has understood the information’ [4]. However, the
‘what’ and ‘how’ of ensuring or verifying that consent is valid (i.e. informed, given voluntarily
and by an individual with capacity) are not specified.
The concept of ‘informed consent’ (both for treatment and for research) is often interpreted
differently and operationalized inconsistently [5, 6]. There is no universally agreed measure of
“good” informed consent for clinical trials that might be used to objectively evaluate whether
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the potential participant has understood what trial participation means for them, or indeed
ensured that all other considerations appropriate to ensure informed consent has been
achieved have been met. A number of trial-specific, condition-specific and more generic mea-
sures of aspects of clinical trial informed consent do exist; however, they have been noted to
have variable operationalisations of informed consent and are collected through a variety of
mechanisms–some reported by the participant themselves; others not [6, 7].
In a previous study, Sand et al [7] provided a useful map of the range of measures available
to measure understanding in informed consent; however, there has been no investigation to
date of the underlying concepts captured by different measures of informed consent (and con-
sequently which concepts may not currently be captured by these instruments), how these
may relate to each other (and more broadly to informed consent) and hence how the choice of
measure might influence the results of a study investigating the quality of informed consent.
We, therefore, undertook a systematic narrative review to:
• critically appraise the evidence on the overall conceptualisation and item content of validated
patient reported measures of informed consent for clinical trials; and
• identify reported core domains of potential importance for informed consent.
Recognizing that the participants’ perspective is of utmost importance when considering
whether the consent process was ‘good’ or not, we focused our review only on patient-reported
measures of informed consent. A consent process can fulfill all of the legal imperatives to
ensure consent is informed from a process perspective i.e. provision of information, discus-
sion, etc. However, only by asking potential participants for their perspectives can judgements
be made about whether or not consent was truly informed. The findings of our review are pre-
sented in this manuscript.
Methods
Search methods for identification of studies
The search strategies were designed by KG in collaboration with a Senior Information Scientist
to identify relevant articles that described the development, and/or validation, of patient
reported measures of informed consent for randomised controlled trials (RCTs). We supple-
mented the MEDLINE and EMBASE strategies with the filter described by Terwee and col-
leagues which identifies studies on measurement properties of measurement instruments [8].
The strategies for each of the databases are presented as text in S1 Appendix. We conducted
searches for relevant studies on the following pre-specified databases:
• MEDLINE (OvidSP) (1946 to 1st September 2016)
• EMBASE (Ovid SP) (1980 to 2016 week 35)
• CINAHL (OvidSP) (1960 to 1st September 2016)
• PsycINFO (OvidSP) (1970 to 1st September 2016)
There were no language nor date restrictions. Table 1 presents number of studies identified
in each database. We combined the results and removed duplicates. Reference lists of included
papers were screened to identify further relevant publications.
Inclusion criteria. The purpose of this review was to identify the items included in vali-
dated measures of RCT informed consent (we did not seek to evaluate the methodological
quality of these measures). However, to ensure the methodology applied was rigorous we fol-
lowed the COnsensus-based Standards for the selection of health Measurement Instruments
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(COSMIN) Protocol for systematic reviews of measurement properties [9]. The following
inclusion criteria were applied:
1. the instruments should aim to measure informed consent (or aspects of) in a clinical trial
context;
2. the study sample should contain potential trial participants;
3. the study should include a questionnaire based measure (to include self-report, adminis-
tered by interview; or by proxy);
4. the aim of the study should be the development of a measurement instrument and evidence
of the evaluation of one or more of its measurement properties;
5. the study should be published as a full text original article;
6. articles in all languages will be assessed for eligibility.
Exclusion criteria.
1. Studies that reported study specific measures with no details on development or validation;
2. Studies that measured informed consent for treatment or for research participation in a
study other than an RCT;
3. Trials or studies evaluating the effectiveness of informed consent interventions where a
questionnaire is used to measure an endpoint (without describing the development of the
tool in full).
Selection of studies. One reviewer (KG) screened all identified titles and abstract with
another reviewer (MC) screening a random 10% sample for consistency. Full text articles were
assessed by one reviewer (KG) for inclusion and a random 30% sample was screened by
another reviewer (MC) for consistency. Any disagreements on eligibility were discussed and
consensus reached.
Data extraction and management
Data extraction forms and tables were generated for each stage of the extraction process to
standardise the information recorded and aid analysis. All data extracted and presented relates
to data pertaining to the study that reported the development and validation of an instrument
to measure informed consent to clinical trials. One review author (KG) independently
extracted data related to study characteristics (e.g. demographics of population, host trial
detail, etc ) and instrument characteristics (e.g. whether theoretically informed, number of
items, etc) from each included study. This was checked by a second reviewer (SC) for accuracy.
General data extraction categories were split into those relating to the context of the included
Table 1. Search results for electronic databases.
Database searched Number of hits
MEDLINE 4244
EMBASE 4001
PsycINFO 1813
CINAHL 1526
TOTAL 11871
After de-duplication 8191
https://doi.org/10.1371/journal.pone.0199775.t001
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informed consent study and those relating to the included informed consent instrument. Spe-
cifically these were:
1. Included study characteristics: country; population; sample size; response rate; age; gender;
ethnicity; employment status; and education status.
2. Included instrument characteristics: name of instrument; theoretical/conceptual frame-
work; construct assessed; time required to complete; recall period; dimensions; patient
reported outcome; response options; ease of scoring and administration; mode of adminis-
tration; sample items; and patient or public involvement in development.
Data extraction and coding relating specifically to content items (i.e. individual questions)
of the instrument was conducted by two reviewers (KG and AD) independently with a random
sample of papers (n = 5) assessed for consistency in overlap between reviewers (by KG). Any
disagreements were resolved through discussion with a third reviewer (MC) if required. Data
extraction was based on the following categories: name of the tool; concept of tool (verbatim
from included study); items (verbatim from included study); construct being targeted by item
(verbatim from included study); domain (as defined by review authors and informed by con-
struct targeted); and sub-domain (as defined by review authors).
Data synthesis
The first step of data synthesis involved the coding of the items identified from the instruments
of included studies into domains and sub-domains determined by the reviewers. This process
followed many of the tenets of ‘directed’ content analysis [10]. Directed content analysis is
guided by a structured approach that uses existing theory (or research) to identify the key con-
cepts as initial coding categories [10]. Our initial proposed coding categories were thus
informed by constructs identified from previously published regulatory guidance and existing
research on informed consent. This was then supplemented by any additional constructs iden-
tified within the included manuscripts. The direct process of assigning appropriate codes to
concepts discussed in manuscripts was primarily informed by consideration of how the
authors reported the underlying construct. Initial allocation of codes was followed by discus-
sion amongst two reviewers (KG and AD) to reach consensus on reviewer determined
domains. This parallel coding process was carried out for 20 (11%) of the items with the
remainder being coded independently by the two reviewers and results compared and dis-
cussed on completion. A third reviewer (MC) coded a random sample of 46% (n = 83) of the
items to offer additional considerations and provide overall agreement on the coding catego-
ries. Items were then agreed across the main domains and sub-domains to provide an overall
perspective of the conceptual framework emerging from these instruments.
Both for descriptions of included studies and of the instruments reported in those studies,
descriptive statistics were used to describe general information and instrument detail. A
narrative synthesis of the instruments and their inter-related domains and subdomains is
presented.
Results
The search identified 8193 citations. After screening titles and abstracts, 29 full text articles
were retrieved for further assessment. Of these 29, 14 complied with our pre-specified inclu-
sion criteria and 15 were not eligible. Reasons for full text articles being deemed not being eli-
gible are reported in Table 2. Full details of the search process can be seen in Fig 1.
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Descriptive characteristics: Included studies
The table in S1 Table summarises the basic characteristics of the included studies [11–24].
Identified studies were published between 1996 and 2013. Eleven of the 14 included studies
were set within the USA, with one further study being multi-site and set across the USA, Can-
ada, Australia and New Zealand. The two remaining studies were conducted in the United
Kingdom and Italy. The clinical trial population in which the informed consent studies were
set varied and ranged across: mental health trials (e.g. depression, schizophrenia); paediatric
trials, oncology trials; and others. All studies included patients as participants (additionally
some studies also involved nurses and others healthy volunteers). This variability was further
reflected in the testing scenario sometimes being a real trial and others being a hypothetical
trial. The size of the sample included in each included study also varied and ranged from nine
to 1086 participants (median = 174). As expected the demographics (e.g. age, gender, ethnicity,
employment and education) of participants in the included studies varied and in some cases
were not reported (see S1 Table).
Descriptive characteristics: Instruments from included studies
Information relating to characteristics of the instruments identified in the included studies is
presented in Table 3. The included studies report 14 separate instruments whose aim is to
measure an aspect of informed consent for RCTs. The included studies varied in their reports
of what the instrument aimed to measure overall and reported concepts such as: ‘therapeutic
Table 2. Excluded studies.
Paper Reason
1 Albrecht TL et al
1999
Measures patient–physician communication in cancer clinical trials. Not focussed on
development of an instrument.
2 Woodward WE et al
1999
Measures level of understanding in population. Not focussed on development of an
instrument
3 Marteau M et al 2001 Develop measure of informed choice in an antenatal screening context i.e. measure not
developed for informed consent for RCTs.
4 Siminoff LA 2003 Not a report of primary research. Discussion.
5 Leroy T et al 2008 Measures level of understanding in population. Not focussed on development of an
instrument.
6 Rounsaville DB et al
2008
Uses a quiz to measure level of understanding in population. Not focussed on
development of an instrument
7 Bhansali S et al 2009 Measures level of understanding in population. Not focussed on development of an
instrument
8 Frew PM et al 2010 Measure is focussed on willingness to participate in a clinical trial, not on informed
consent.
9 Ballard HO et al 2011 Standard versus enhanced consent process. Not focussed on development of an
instrument.
10 Behrendt C et al 2011 Measures level of understanding in population. Not focussed on development of an
instrument
11 Cohn CG et al 2011 Measures informed consent but is not a PROM
12 Leroy T et al 2011 Measures level of understanding in population. Not focussed on development of an
instrument.
13 Shafiq N et al 2011 Reports the questionnaire items from a study that measured levels of understanding in
population. Not focussed on the development of an instrument
14 Horowitz RH et al
2013
Measures level of understanding in population. Not focussed on development of an
instrument
15 Mexas et al 2014 Provides no formal analysis of test retest data to support validation of measurement
properties.
https://doi.org/10.1371/journal.pone.0199775.t002
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misconception’; ‘therapeutic misunderstanding’; ‘perceived understanding’; ‘patient understand-
ing of research’; ‘clinical trial understanding’; ‘understanding information’; ‘comprehension of
informed consent information’; ‘understanding and retention of trial information’; ‘maintaining
informed consent’ (operationalised through repeated measurement); ‘quality of informed
consent’; ‘evaluation to consent’ (relates to evaluating capacity); ‘autonomous authorisation’;
‘assessing decisional capacity’; and ‘decision making’. Four of the included studies reported
development of an instrument to assess competence, or capacity, of research subjects to con-
sent to participation in RCTs i.e. the studies were set amongst participants who may have
diminished decisional capacity e.g. early stage Alzheimer’s, schizophrenia. [11,16, 23, 24].
Of the 14 instruments, three explicitly reported a theoretical or conceptual framework
underpinning their development (theories of therapeutic misunderstandings and or miscon-
ception [12, 13, 17]): a further two [22, 24] implicitly referred to the ‘conceptual dimensions of
informed consent’ or ‘principles of research ethics’ as informing their development and nine
Fig 1. PRISMA flow diagram for identification of included studies in informed consent for RCTs patient reported measures review.
https://doi.org/10.1371/journal.pone.0199775.g001
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reported no guiding theoretical framework. Linked to this, some instruments were explicit
with regard to which constructs they were measuring while others were more vague.
The time required to complete the measure ranged from less than 5 to 20 minutes (median
8.4 mins). Five studies did not report time required to complete [13, 14, 20, 22, 23] and one
reported completion time as ‘study procedures’ that included additional procedures as well as
instrument completion [12]. Half of the included studies did not report the recall period
assessed using the instrument with the seven remaining studies varying from point of consent
to 10 weeks post consent.
The number of items per instrument varied across the 14 measures and ranged from 5 to 34
(median = 14) with a cumulative total of 179 individual items. There was some level of duplica-
tion or overlap across the 179 items. Specifically, 156 (87%) measured understanding or
knowledge of domains, nine items (5%) measured decisional control (and focused on per-
ceived voluntariness with all items identified from one tool [20]), eight items (4%) measured
appreciation (of aspects such as expectations and consequences of participation) and six items
(3%) measured reasoning. All of the appreciation and reasoning items are attributable to two
tools that both aimed to measure patient’s competence or capacity to consent for research [11,
16]. Response options of instruments also varied with some being open-ended responses and
others being Likert type questions. Mode of administration also varied with the majority being
self-completed but others being administered by trained interviewers either face-to-face or
over the telephone.
Finally, five of the 14 studies reported patient or public involvement during some stage in
the development of the tool [12, 14, 15, 17, 20]. Two studies directly involved patients in iden-
tifying core content for inclusion in the tool [15, 20]; one study involved patients in reviewing
and modifying the tool before piloting [14]; and two studies worked with patients during the
piloting of the tool [12, 17].
Item domain and sub-domain classification
As mentioned above, the majority of items contained across all measures assess participants
understanding in relation to specific features of the trials. Other aspects of cognition reported
to be measured related to decisional control, reasoning, and appreciation. To identify which
aspects of understanding were being assessed, we coded individual items into domains and
sub-domains that broadly captured the underlying construct being measured (as described in
the Methods section). Table 4 presents a summary of the item classification, including defini-
tions (with example items), according to coded domains and subdomains. S1 Text provides
coding of all items across the included instruments.
Our review identified five core domains across the 179 items (which spanned the core cog-
nitive concepts of understanding, decisional control, appreciation, and reasoning). These core
domains were constructed as: Autonomy; Consequences; Expectations; Purpose; and Indivi-
dualisation. These domains are conceptually distinct but some are more intimately connected
than others e.g. consequences and expectations. Consequences (n = 62) and purpose (n = 66)
were the most commonly identified domains and individualisation (n = 8) the least. These
core domains could be further categorised into discrete subdomains. Including: aim (of the
trial to which they were consenting); alternatives; benefit; confidentiality; disadvantage or risk
(of interventions); experience; motivations; positive beliefs; process; randomisation; satisfac-
tion; therapeutic misconception; uncertainty; and voluntariness. The most commonly identi-
fied subdomain was ‘benefit’ (n = 35/20%) and ‘motivations’ the least (n = 1 / 0.5%). It is
important to note that subdomains were not exclusively linked to one core domain. For exam-
ple, ‘process’ was associated with all domains whereas ‘confidentiality’ was only linked to
Patient reported measures of informed consent for clinical trials: A systematic review
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‘consequences’ and ‘purpose’. Fig 2 provides an overview of the relational intersections of sub-
domains across core domains identified in patient reported measures of informed consent for
clinical trials.
Table 5 provides a summary of domain content identified in the informed consent mea-
sures included in our review. Fourteen of the included instruments could be classed as being
multi-dimensional based on their coded domains. The Index of Clinical Trial Understanding
(ICTU) was the only measure that could be considered unidimensional due to it exclusively
including items that could be coded to one domain: purpose [19]. However, within the pur-
pose domain, the ICTU patient reported measure did capture aspects relating to aim, process
and randomisation. Across the 14 patient reported measures, only 1 included all 5 identified
domains: the MacArthur Competence Assessment Tool–Clinical Research (MacCAT-CR)
[11]. The MacCAT-CR was developed to assess depressed patients capacities to consent to
research and covers cognitive aspects of appreciation and reasoning in addition to understand-
ing [11].
Discussion
This review of patient reported measures for informed consent for clinical trials is, to our
knowledge, one of the first to systematically characterise the item content across these mea-
sures into individual outcome domains highlighting the heterogeneity that exists across out-
come measures reporting to capture the same outcome. Importantly, this review further
Table 4. Domains and subdomains identified across individual items of measures identified in the review.
Domain (N (%)) Definition Subdomain (N (%))Content relates to
understanding of specific sub domain.
Autonomy 26 (15) A potential participant’s right to make choices, to
hold views, and to take actions based on personal
values and beliefs.e.g. Are you required to participate
in this research study?
Motivation—1 (4) Process—1 (4)
Voluntariness—24 (92)
Consequences 62
(35)
Any event that occurs as a result of participating in
the trial and are contingent on participation.
Consequences can be reinforcers (i.e. increase
participation) or punishers (i.e. decrease
participation).e.g. Do you feel that the potential
benefits of participation in this study were explained?
Alternatives—4 (6) Benefit—29 (46)
Benefit/Risk—5 (8) Confidentiality- 4
(6)
Disadvantage/Risk- 13 (21) Process -3
(5)
Voluntariness -5 (8)
Expectations 17 (9) Beliefs about what will (or did) happen when
participating in the trial. Tends to focus on the
future. Can give rise to disappointment if a less than
favourable outcome occurs.e.g. Were the treatments
more difficult than you expected?
Experience—3 (18) Positive Beliefs -2
(12) Process—8 (47) Satisfaction—4
(23)
Purpose 66 (37) The specific aim or process requirements of the
study.e.g. Were the treatments more difficult than you
expected?
Aim -8 (12) Alternatives- 1 (1) Benefit-
6 (9) Benefit/Risk—9 (14)
Confidentiality—1 (1)
Process—13 (20)
Randomisation - 15 (23) Therapeutic
misconception—10 (16)
Uncertainty—2 (3)
Voluntariness– 1 (1)
Individualisation 8
(4)
The belief that treatment choices will be
individualised for the potential trial participants
specific needs.e.g. The treatment /intervention I
would receive in this study will be adapted according
to my needs, like the treatment from any other doctor.
Process– 1 (12.5)
Therapeutic Misconception—6 (75)
Voluntariness—1 (12.5)
Benefit/Risk: These items were assessing understanding of both benefit and risk information together
https://doi.org/10.1371/journal.pone.0199775.t004
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underlines the predominant lack of input from potential trial participants during development
to aid in identification of what aspects of the informed consent process for trials matters to
participants and should therefore be considered important for measurement when assessing
the process–a perfect contradiction.
We identified 179 individual items across 14 instruments, the majority of which (87%)
assessed understanding, and the items of which could be conceptualised into 5 core domains:
Autonomy; Consequences; Expectations; Purpose; and Individualisation. A range of discrete
subdomains were identified across these core domains relating to content, such as: aim; bene-
fit; disadvantage or risk; satisfaction; therapeutic misconception. The majority of instruments
were multidimensional although the coverage of domains was highly variable with most mea-
sures only addressing a subset of domains–with one measure (ICTU) being unidimensional in
its content. This variability in coverage and focus of the measures make any future wish to
synthesise outcome data from across these measures problematic, suggesting the need for the
development of a core outcome set to inform the domains that all future studies should report.
This work is now in development by the authors [25].
Our review showed that the majority of instruments lacked a theoretical framework to
inform their development. This calls into question their construct validity (i.e. the extent to
which the instrument tests the theory it is measuring) and raises concerns about their ability to
accurately measure the underlying concept of informed consent. In other words, our review
Fig 2. Conceptual diagram of domains from RCT informed consent validated measures.
https://doi.org/10.1371/journal.pone.0199775.g002
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may have failed to identify domains and sub-domains of relevance for informed consent to
clinical trials due to the lack of key content included in the instrument development. Measures
that did report the use of theory to inform their development also varied in their conceptuali-
sation of informed consent and as such associated domains and sub-domains relating to con-
structs varied. Thus providing further evidence that the over-arching concept (in this case
‘informed consent to trials’) which they aim to measure is likely not the same between
measures.
Whilst all included instruments were patient–reported, only three included trial partici-
pants or patients in the development phase pre-pilot. This lack of stakeholder input also raises
questions about content validity and specifically whether these measures represent items that
are of importance to potential trial participants [25].
Our review further highlighted the dominant focus of measures on the “understanding”
of trial specific information–this concentration on understanding has also been raised by
a number of other commentators [6,7, 26]. Whilst understanding of information is an impor-
tant component of clinical trials informed consent, many of the existing measures lack
Table 5. Inclusion of core domains across included measures ranked by frequency of domains.
Instrument Autonomy Consequences Expectations Purpose Individualisation # of
domains
MacArthur Competence
Assessment Tool–Clinical
Research (MacCAT-CR)
+ + + + + 5
Quality of Informed
Consent (QuIC)
+ + + + - 4
University of California,
San Diego Brief Assessment
of Capacity to Consent
(UBACC)
+ + + + - 4
Deaconess Informed
Consent Comprehension
Test (DICCT)
+ + + + - 4
Evaluation to Sign Consent
(ESC)
+ + + + - 4
Brief Informed Consent
Evaluation protocol
(BICEP)
+ + + + - 4
Therapeutic
Misunderstanding Scale
(TMU)
- + + + + 4
Therapeutic Misconception
(TM)
- + - + + 3
Informed Consent
Questionnaire(ICQ)
- + + + - 3
Questionnaire-Patient
Understanding of Research
(Q-PUR)
+ + - + - 3
Porteri et al (2007) + + - + - 3
Assessment of Sustained
Informed Consent (ASIC)
+ - + + - 3
Decision Making Control
Instrument (DMCI)
+ - - - + 2
Index of Clinical Trial
Understanding (ICTU)
- - - + - 1
Total count across tools 10 11 9 13 4
https://doi.org/10.1371/journal.pone.0199775.t005
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consideration of other aspects that might be important for the decision making process (e.g.
preference construction, affective forecasting and integration of information with personal val-
ues and goals) [27, 28]. Only a few studies have measured and reported specific decision mak-
ing outcomes (such as decision conflict, decision regret and deliberation) during the informed
consent process [29–34]. Interventions that aim to provide a more holistic approach to
informed consent and go beyond solely seeking to improve understanding of trial information
(by considering aspects of decision making that could also be important) are needed [28, 32,
33, 35]. As these decision-focused, and other, interventions to support the informed consent
process for clinical trials become more widespread, it is likely that the instruments used to
evaluate their effectiveness will also progress. Ideally, this progress should include involving
potential trial participants in instrument development and evaluation.
Strengths and limitations
This study included a detailed systematic search to identify patient reported measures of
informed consent to clinical trials and included rigorous methods to identify and code relevant
domains across included patient reported measures. Searching was applied across a range of
databases and incorporated search filters designed to ensure wide coverage and capture of rele-
vant measurement tools. It included studies from a variety of trial contexts and geographical
settings which maximises the relevance of review to different settings. It does, however, have
some weaknesses. The coding of items was conducted by two authors independently with a
third author checking a random sub-sample. The coding was informed by directed content
analysis, which has some level of interpretation required during the analysis. Therefore, whilst
a systematic and rigorous approach, like many qualitatively interpretive approaches it is sub-
jective and it is possible that if conducted by other researchers (with different perspectives and
lenses) that a different overall result may emerge. No formal assessment of inter-rater reliabil-
ity was conducted, however, informal assessments of consistency did not highlight any major
problems. In addition, we did not conduct any formal assessment of the methodological qual-
ity of instruments identified in included studies. Whilst this was not the aim of the study it
could have provided a conclusion about which (if any) of the existing measures is the most
methodologically sound.
Conclusions
This study has demonstrated the variability in the theoretical underpinning, development and
domain coverage of existing patient-reported measures of informed consent for clinical trials.
The dominant focus of tools to date has been limited to measuring understanding of items
deemed important by researchers—the conceptualisation of informed consent could benefit
from being extended to include broader considerations of decision-making. Meaningful
involvement of potential trial participants during development of measures ‘critical for tool
relevance’ is also lacking. The findings from this work provide evidence to support efforts to
identify the key domains (of relevance to all stakeholders) which could be measured to assess
the adequacy of the existing (and efforts to improve) informed consent process for clinical
trials.
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